Inbrija (levodopa inhalation powder) — United Healthcare
Parkinson’s disease with OFF episodes
Initial criteria
- Diagnosis of Parkinson’s disease
- Used as intermittent treatment for OFF episodes
- Patient is currently on and will continue to receive treatment with a carbidopa/levodopa-containing medication
Reauthorization criteria
- Documentation of positive clinical response to Inbrija therapy
- Patient will continue to receive treatment with a carbidopa/levodopa-containing medication
Approval duration
12 months